Bristol-Myers CEO calls new cancer drug biggest opportunity
This article was originally published in Scrip
An experimental treatment that enables the immune system to fight cancer is the biggest market opportunity for Bristol-Myers Squibb near term, and the company is unfazed by rival Merck & Co’s plan for an early filing for a similar drug to treat melanoma.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.